Abstract
The diagnostic entity of clear cell carcinoma of the lung (CCCL) is controversial, with many investigators arguing against its inclusion in the World Health Organization classification of lung carcinoma. Because of its rarity and questions regarding its histogenesis, I studied 3 groups of carcinomas with immunohistochemical and molecular assays, including 6 cases of CCCL, 7 cases of adenocarcinoma with clear cell change, and 11 cases of squamous carcinomas with prominent clear cell change. CCCL tended to be present in older individuals with an adenocarcinoma immunophenotype (cytokeratin 7 and TTF1 positivity). Molecular analysis by Sanger sequencing revealed KRAS mutations in 5 of 6 cases of CCCL, 2 of 7 adenocarcinomas with clear cell change, and 2 of 11 squamous carcinomas with clear cell change. Although perhaps not a distinct pathologic entity, in this pilot study, CCCL has an immunophenotype similar to solid-type adenocarcinoma with clear cell change and displays more frequent and unusual KRAS mutations than expected in most adenocarcinomas of the lung.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
